{"product_id":"vstm-marketing-mix","title":"(VSTM) Verastem, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Verastem, Inc. 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategy so you can see how its oncology portfolio is positioned and marketed; the page includes a real preview\/sample of the analysis so you can evaluate style and substance before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVS-6766 dual RAF\/MEK inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem’s lead product, VS-6766, is a dual RAF\/MEK inhibitor that uses a clamp mechanism to block MEK kinase activity and RAF-driven MEK phosphorylation. As of July 2026, it remains the company’s core platform asset in its pipeline and market story. Its main value is clinical differentiation in RAS\/MAPK-driven cancers, where Verastem is still built around this single lead program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDefactinib oral FAK inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDefactinib is an oral small-molecule focal adhesion kinase inhibitor, and Verastem pairs it with VS-6766 in multiple studies. In 2025, this 2-drug strategy helped widen the oncology pipeline beyond a single asset and support a more durable franchise. It also gives Verastem more than 1 path to value creation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRAMP 201 recurrent LGSOC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRAMP 201 is a multicenter, randomized, open-label study testing VS-6766 alone and with defactinib in recurrent low-grade serous ovarian cancer. It supports Verastem, Inc.'s product validation by checking both tumor response and combination value in a hard-to-treat niche. The readout can sharpen Verastem, Inc.'s positioning for a rare cancer with limited standard options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRAMP 202 NSCLC KRAS and BRAF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRAMP 202 is Verastem, Inc.'s Phase 2 study of VS-6766 plus defactinib in NSCLC with KRAS or BRAF mutations after platinum-based therapy and immune checkpoint inhibitors. It targets a small, genetically defined oncology group, which can improve trial precision and commercial focus. Phase 2 data matter here because the setting is late-line, mutation-selected lung cancer, where response signals can support the 4P \"Product\" case.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 2: RAMP 202\u003c\/li\u003e\n\u003cli\u003eCombo: VS-6766 + defactinib\u003c\/li\u003e\n\u003cli\u003ePopulation: KRAS\/BRAF NSCLC\u003c\/li\u003e\n\u003cli\u003eSetting: post-platinum, post-ICI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRAMP 203 VS-6766 plus LUMAKRAS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRAMP 203 pairs Verastem, Inc.’s VS-6766 with Amgen’s LUMAKRAS in a Phase 1\/2 study, testing a KRAS-G12C inhibitor plus a RAF\/MEK clamp in solid tumors. It pushes Verastem, Inc. deeper into combination-based precision oncology, where response depth and resistance control matter most. The combo strategy can widen the commercial use case beyond monotherapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 1\/2 combo trial\u003c\/li\u003e\n\u003cli\u003eVS-6766 plus LUMAKRAS\u003c\/li\u003e\n\u003cli\u003eTargets KRAS-driven tumors\u003c\/li\u003e\n\u003cli\u003eExpands precision oncology reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem’s Narrow but Focused 2025-2026 Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem’s Product mix in 2025-2026 centers on VS-6766, a dual RAF\/MEK clamp, and defactinib, an oral FAK inhibitor. The pair anchors RAMP 201, 202, and 203, targeting low-grade serous ovarian cancer, KRAS\/BRAF NSCLC, and KRAS-driven solid tumors. This makes the pipeline narrow but clinically focused.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVS-6766\u003c\/td\u003e\n\u003ctd\u003eRAF\/MEK clamp\u003c\/td\u003e\n\u003ctd\u003eCore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDefactinib\u003c\/td\u003e\n\u003ctd\u003eFAK inhibitor\u003c\/td\u003e\n\u003ctd\u003eCombo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLUMAKRAS combo\u003c\/td\u003e\n\u003ctd\u003eKRAS-G12C\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, company-specific breakdown of Verastem, Inc.’s Product, Price, Place, and Promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDistills Verastem’s 4Ps into a quick, decision-ready snapshot that simplifies strategy review and internal alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable list of primary and reputable sources that validate Verastem’s market, pricing, and competitive assumptions to speed due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeedham Massachusetts headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. is headquartered in Needham, Massachusetts, and this site serves as its corporate base for development, partnership, and operating decisions. As a clinical-stage oncology company, Verastem runs a lean model with no retail stores or distributor network, so the Needham office anchors a 100% corporate and R\u0026amp;D-led setup. That fits a 2025-style pharma mix built around one HQ, not a sales floor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulticenter clinical sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. places its products through multicenter clinical trial networks, with RAMP 201 and RAMP 202 using trial sites to reach patients across geographies. In biopharma, these sites are the main access point before commercial launch, so site quality and enrollment speed shape real market reach. That matters because trial-site execution can affect time to data, and time to data affects future sales timing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-led commercialization rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. uses a partner-led place strategy for VS-6766: under its Chugai deal, Chugai holds development, commercialization, and manufacturing rights for VS-6766-based products in its territory. That expands market access beyond Verastem, Inc.'s own sales reach and lowers the need for a full in-house launch build. In practice, partner control of supply and local selling can speed entry and widen reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCollaborative development channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc. uses partnerships as a low-cost route to extend VS-6766 development and reach. The Amgen agreement backs clinical studies of VS-6766 combinations, while Pfizer and Chugai widen scientific access and add external operating reach, which matters for a company still in late-stage development and pre-commercial scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAmgen supports clinical combo work\u003c\/li\u003e\n\u003cli\u003ePfizer expands partner reach\u003c\/li\u003e\n\u003cli\u003eChugai broadens scientific access\u003c\/li\u003e\n\u003cli\u003ePartnerships act as indirect market routes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDirect specialty oncology access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem’s place strategy is narrow and clinical: its oncology products are aimed at oncologists, research centers, hospitals, academic medical centers, and trial sites, not consumers. That is typical for a clinical-stage cancer company, where access is driven by specialist prescribing and study enrollment rather than retail distribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialist-only access\u003c\/li\u003e\n\u003cli\u003eHospital and academic focus\u003c\/li\u003e\n\u003cli\u003eTrial-center driven reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis model keeps distribution concentrated where complex cancer care happens and where patient testing, monitoring, and evidence generation are already in place.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem’s Specialist-Led Access Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. uses a narrow place model: its Needham, Massachusetts HQ anchors all corporate control, while access to patients runs through multicenter oncology trial sites. In 2025, this keeps reach specialist-led, not retail-led, and lowers the need for a broad sales footprint. Partner deals, including Chugai rights for VS-6766 in its territory, extend market access without building a full local network.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace lever\u003c\/th\u003e\n\u003cth\u003eCurrent setup\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003eNeedham, Massachusetts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess path\u003c\/td\u003e\n\u003ctd\u003eClinical trial sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner reach\u003c\/td\u003e\n\u003ctd\u003eChugai territorial rights\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVerastem, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the exact version of the Verastem, Inc. 4P's Marketing Mix Analysis you'll download immediately after checkout, fully complete and ready to use.\u003c\/p\u003e\n\u003cp\u003eThis file is the real, high-quality marketing mix report included with your purchase—editable and comprehensive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial disclosures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem uses public trial disclosures as a low-cost promotion channel, centered on RAMP 201, RAMP 202, and RAMP 203. These updates keep the pipeline visible and help explain its differentiation in oncology. In 2025, the company still relied on clinical data releases, not mass-market ads, to build awareness and support investor interest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific data readouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. uses scientific data readouts as its core promotion engine, with oncology efficacy and safety data driving the message. Trial endpoints like ORR, PFS, and duration of response are front and center, plus mutation-specific cohorts that help show who benefits most. In RAMP 201, the combo reported a 44% objective response rate in KRAS-mutant recurrent low-grade serous ovarian cancer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner announcements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem uses partner announcements to widen market visibility, and its links with Chugai, Pfizer, and Amgen give outside validation. In biopharma, collaboration news is a key promo tool because it can lift credibility fast; Verastem’s 3 named large-cap partners do that well. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInvestor relations communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc. uses investor relations to share pipeline updates, trial milestones, and strategy with shareholders, analysts, and institutions. As a public company, its value is shaped by timely disclosures on clinical progress and capital needs, especially as it advances oncology programs in a market where one delayed trial update can move the stock fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShares trial status and key milestones\u003c\/li\u003e\n\u003cli\u003eExplains pipeline and strategy shifts\u003c\/li\u003e\n\u003cli\u003eTargets shareholders and analysts\u003c\/li\u003e\n\u003cli\u003eSupports trust with corporate updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrecision oncology positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc. promotes precision oncology by focusing on biomarker-defined tumors, not broad cancer pools. Its messaging centers on 3 named areas: KRAS, BRAF, and low-grade serous ovarian cancer, which helps the Company stand out from larger oncology peers that market across many indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 priority programs sharpen the message\u003c\/li\u003e\n\u003cli\u003eBiomarkers guide patient selection\u003c\/li\u003e\n\u003cli\u003eNarrow focus supports clearer differentiation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem’s 2025 Growth Was Driven by Trial Data, Not Ads\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc.’s promotion in 2025 stayed data-led: trial readouts, investor updates, and partner news did the heavy lifting. The sharpest proof point was RAMP 201, where avutometinib + defactinib posted a 44% objective response rate in KRAS-mutant recurrent low-grade serous ovarian cancer. This kept the brand visible without mass-market ads.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial readouts\u003c\/td\u003e\n\u003ctd\u003eRAMP 201, 202, 203\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore metric\u003c\/td\u003e\n\u003ctd\u003e44% ORR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner messaging\u003c\/td\u003e\n\u003ctd\u003eChugai, Pfizer, Amgen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo approved commercial price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of July 2026, Verastem, Inc. has no broadly marketed approved product, so there is no public consumer list price for its lead assets. Pricing is still tied to development-stage programs, where value is set by clinical data, trial progress, and future reimbursement paths. In this phase, the market price is effectively undisclosed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrial access not patient priced\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial access in Verastem, Inc. RAMP studies is sponsor funded, so patients do not pay a retail drug price. The economic model is research access, not commercial sale, which keeps out-of-pocket cost at $0 for the study drug. That fits the usual trial setup: the sponsor covers the investigational product, while pricing only starts after approval and launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture specialty oncology pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf approved, VS-6766-based therapies would likely price in the specialty oncology band, where many targeted cancer drugs launch above $100,000 a year. Biomarker targeting and combination use usually justify premium pricing, but they also lift total treatment cost. Reimbursement will hinge on payor coverage, real-world outcomes, and evidence of clinical value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner economics undisclosed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartner economics for Verastem, Inc. are not fully public, so the exact price split is unclear. Revenue could still be shaped by milestones, royalties, and shared development value from Chugai, Pfizer, and Amgen links, but the contract terms are undisclosed.\u003c\/p\u003e\n\u003cp\u003eThat matters because even a single milestone can move near-term cash, while royalties can support longer-term sales. Without a public price schedule, the best read is that economics are relationship-based, not fixed and fully transparent.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExact price structure is undisclosed\u003c\/li\u003e\n\u003cli\u003eMilestones may affect cash flow\u003c\/li\u003e\n\u003cli\u003eRoyalties may support future revenue\u003c\/li\u003e\n\u003cli\u003eShared development value is possible\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eValue based market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc. uses value based market access because oncology prices are tied to survival gain, safety, and unmet need. Its mutation-specific studies, including the RAMP-201 program in recurrent low-grade serous ovarian cancer, support a pay-for-value case rather than broad volume selling.\u003c\/p\u003e\n\u003cp\u003eAny launch price would likely hinge on response data and payer talks, not unit count. In a niche cancer segment, even a 40% plus response rate can matter more than scale if reimbursement is secured.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue linked to outcomes.\u003c\/li\u003e\n\u003cli\u003eMutation-specific trials support pricing.\u003c\/li\u003e\n\u003cli\u003ePayer access drives launch success.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem Pricing: $0 in Trial, Potentially $100K+ at Launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of July 2026, Verastem, Inc. has no approved product, so there is no public list price. RAMP study access is sponsor funded, so patients pay $0 for the investigational drug. If launched, VS-6766 could fit specialty oncology pricing, often above $100,000 a year, with reimbursement tied to outcomes and payer talks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003ePrice view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved product\u003c\/td\u003e\n\u003ctd\u003eNo public price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial access\u003c\/td\u003e\n\u003ctd\u003e$0 patient cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLikely launch band\u003c\/td\u003e\n\u003ctd\u003eAbove $100,000\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235165413641,"sku":"vstm-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vstm-marketing-mix.webp?v=1785735652","url":"https:\/\/dcfanalyst.com\/products\/vstm-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}